pubmed.ncbi.nlm.nih.gov

Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice - PubMed

️Wed Jan 01 2020

Review

Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice

Ted J Kaptchuk et al. BMJ. 2020.

Abstract

Despite their ubiquitous presence, placebos and placebo effects retain an ambiguous and unsettling presence in biomedicine. Specifically focused on chronic pain, this review examines the effect of placebo treatment under three distinct frameworks: double blind, deception, and open label honestly prescribed. These specific conditions do not necessarily differentially modify placebo outcomes. Psychological, clinical, and neurological theories of placebo effects are scrutinized. In chronic pain, conscious expectation does not reliably predict placebo effects. A supportive patient-physician relationship may enhance placebo effects. This review highlights "predictive coding" and "bayesian brain" as emerging models derived from computational neurobiology that offer a unified framework to explain the heterogeneous evidence on placebos. These models invert the dogma of the brain as a stimulus driven organ to one in which perception relies heavily on learnt, top down, cortical predictions to infer the source of incoming sensory data. In predictive coding/bayesian brain, both chronic pain (significantly modulated by central sensitization) and its alleviation with placebo treatment are explicated as centrally encoded, mostly non-conscious, bayesian biases. The review then evaluates seven ways in which placebos are used in clinical practice and research and their bioethical implications. In this way, it shows that placebo effects are evidence based, clinically relevant, and potentially ethical tools for relieving chronic pain.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PubMed Disclaimer

Conflict of interest statement

Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: none.

Cited by

Psychological Predictors of Response to Open-Label Versus Double-Blind Placebo in a Randomized Controlled Trial in Irritable Bowel Syndrome.
Ballou S, Haas JW, Iturrino J, Nee J, Kirsch I, Rangan V, Cheng V, Lembo A, Kaptchuk TJ, Kelley JM. Ballou S, et al. Psychosom Med. 2022 Jul-Aug 01;84(6):738-746. doi: 10.1097/PSY.0000000000001078. Epub 2022 Apr 12. Psychosom Med. 2022. PMID: 35412513 Free PMC article. Clinical Trial.
Factors That Predict Magnitude, Timing, and Persistence of Placebo-Like Response in Patients With Irritable Bowel Syndrome.
Lackner JM, Quigley BM, Zilcha-Mano S, Radziwon C, Krasner SS, Gudleski GD, Enck P. Lackner JM, et al. Gastro Hep Adv. 2024;3(2):221-229. doi: 10.1016/j.gastha.2023.10.003. Epub 2023 Oct 14. Gastro Hep Adv. 2024. PMID: 38456188 Free PMC article.
"Let's see what happens:"-Women's experiences of open-label placebo treatment for menopausal hot flushes in a randomized controlled trial.
Pan Y, Frank ML, Kaptchuk TJ, Nestoriuc Y. Pan Y, et al. PLoS One. 2022 Nov 4;17(11):e0276499. doi: 10.1371/journal.pone.0276499. eCollection 2022. PLoS One. 2022. PMID: 36331921 Free PMC article. Clinical Trial.
Functional neurological disorder and placebo and nocebo effects: shared mechanisms.
Fiorio M, Braga M, Marotta A, Villa-Sánchez B, Edwards MJ, Tinazzi M, Barbiani D. Fiorio M, et al. Nat Rev Neurol. 2022 Oct;18(10):624-635. doi: 10.1038/s41582-022-00711-z. Epub 2022 Sep 8. Nat Rev Neurol. 2022. PMID: 36075980 Review.
Placebo, nocebo: Believing in the field of medicine.
Meissner K. Meissner K. Front Pain Res (Lausanne). 2022 Jul 29;3:972169. doi: 10.3389/fpain.2022.972169. eCollection 2022. Front Pain Res (Lausanne). 2022. PMID: 35965595 Free PMC article. No abstract available.

Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice - PubMed